Meropenem anhydrous
Brand names,
Meropenem anhydrous
Analogs
Meropenem anhydrous
Brand Names Mixture
Meropenem anhydrous
Chemical_Formula
C9H11Cl2N3O4S2
Meropenem anhydrous
RX_link
http://www.rxlist.com/cgi/generic3/methyclothiazide.htm
Meropenem anhydrous
fda sheet
Meropenem anhydrous
msds (material safety sheet)
Meropenem anhydrous
Synthesis Reference
No information avaliable
Meropenem anhydrous
Molecular Weight
360.239 g/mol
Meropenem anhydrous
Melting Point
225 oC
Meropenem anhydrous
H2O Solubility
11.2 mg/L
Meropenem anhydrous
State
Solid
Meropenem anhydrous
LogP
0.604
Meropenem anhydrous
Dosage Forms
Tablet for oral administration (5 mg)
Meropenem anhydrous
Indication
For use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Also used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Meropenem anhydrous
Pharmacology
Methyclothiazide, a diuretic-antihypertensive agent, is a member of the benzothiadiazine (thiazide) class of drugs. Methyclothiazide has a per mg natriuretic activity approximately 100 times that of the prototype thiazide, chlorothiazide. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic/natriuretic effects. Like other benzothiadiazines, methyclothiazide also has antihypertensive properties, and may be used for this purpose either alone or to enhance the antihypertensive action of other drugs.
Meropenem anhydrous
Absorption
Rapidly absorbed following oral administration.
Meropenem anhydrous
side effects and Toxicity
Acute oral toxicity (LD50): >4000 mg/kg [Rat]. Symptoms of overdosage include electrolyte imbalance and signs of potassium deficiency such as confusion, dizziness, muscular weakness, and gastrointestinal disturbances.
Meropenem anhydrous
Patient Information
No information avaliable
Meropenem anhydrous
Organisms Affected
Humans and other mammals